Filter

Refine by collections

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 10 of 16 items for :

  • "dose reduction" x
Clear All
Nelma Veronica Marques Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Search for other papers by Nelma Veronica Marques in
Google Scholar
PubMed Close
,
Luiz Eduardo Armondi Wildemberg Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Search for other papers by Luiz Eduardo Armondi Wildemberg in
Google Scholar
PubMed Close
, and
Monica R Gadelha Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Search for other papers by Monica R Gadelha in
Google Scholar
PubMed Close

dose reduction in two patients because of substantial IGF1 reduction ( 5 ). Herein, we present a retrospective analysis of a subset of patients who received long-term treatment with pasireotide, who maintained their biochemical response and had

Article Type:
Research Article
Collections:
Pituitary and Hypothalamus
DOI:
https://doi.org/10.1530/EC-23-0155
Volume/Issue:
Volume 12: Issue 10
Open access
Jennifer Walsh The Mellanby Centre for Bone Research, The Medical School, The University of Sheffield, Sheffield, UK

Search for other papers by Jennifer Walsh in
Google Scholar
PubMed Close
,
Neil Gittoes Centre for Endocrinology, Diabetes and Metabolism, University Hospitals Birmingham & University of Birmingham, Birmingham Health Partners, Birmingham, UK

Search for other papers by Neil Gittoes in
Google Scholar
PubMed Close
,
Peter Selby Department of Medicine, Manchester Royal Infirmary, Manchester, UK

Search for other papers by Peter Selby in
Google Scholar
PubMed Close
, and
the Society for Endocrinology Clinical Committee The Society for Endocrinology, 22 Apex Court, Woodlands, Bradley Stoke, Bristol, UK

Search for other papers by the Society for Endocrinology Clinical Committee in
Google Scholar
PubMed Close

Pamidronate 30–90 mg (depending on severity of hypercalcaemia) at 20 mg/h OR Ibandronic acid 2–4 mg Give more slowly and consider dose reduction in renal impairment Monitor serum calcium response: will reach nadir at 2–4 days Can cause hypocalcaemia

Article Type:
Other
DOI:
https://doi.org/10.1530/EC-16-0055
Volume/Issue:
Volume 5: Issue 5
Open access
Martin Zweifel Department of Medical Oncology, University Hospital Bern, Bern, Switzerland

Search for other papers by Martin Zweifel in
Google Scholar
PubMed Close
,
Beat Thürlimann Breast Centre St. Gallen, Kantonsspital St. Gallen, St. Gallen, Switzerland

Search for other papers by Beat Thürlimann in
Google Scholar
PubMed Close
,
Salome Riniker Breast Centre St. Gallen, Kantonsspital St. Gallen, St. Gallen, Switzerland

Search for other papers by Salome Riniker in
Google Scholar
PubMed Close
,
Patrik Weder Breast Centre St. Gallen, Kantonsspital St. Gallen, St. Gallen, Switzerland

Search for other papers by Patrik Weder in
Google Scholar
PubMed Close
,
Roger von Moos Kantonsspital Graubünden, Chur, Switzerland

Search for other papers by Roger von Moos in
Google Scholar
PubMed Close
,
Olivia Pagani Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland

Search for other papers by Olivia Pagani in
Google Scholar
PubMed Close
,
Martin Bigler SAKK Coordinating Centre, Bern, Switzerland

Search for other papers by Martin Bigler in
Google Scholar
PubMed Close
,
Karin M Rothgiesser SAKK Coordinating Centre, Bern, Switzerland

Search for other papers by Karin M Rothgiesser in
Google Scholar
PubMed Close
,
Christiane Pilop SAKK Coordinating Centre, Bern, Switzerland

Search for other papers by Christiane Pilop in
Google Scholar
PubMed Close
,
Hanne Hawle SAKK Coordinating Centre, Bern, Switzerland

Search for other papers by Hanne Hawle in
Google Scholar
PubMed Close
,
Peter Brauchli SAKK Coordinating Centre, Bern, Switzerland

Search for other papers by Peter Brauchli in
Google Scholar
PubMed Close
,
Coya Tapia Institute of Pathology, University of Bern, Bern, Switzerland

Search for other papers by Coya Tapia in
Google Scholar
PubMed Close
,
Wolfgang Schoenfeld CURADIS GmbH, Erlangen, Germany

Search for other papers by Wolfgang Schoenfeld in
Google Scholar
PubMed Close
,
Cristiana Sessa Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland

Search for other papers by Cristiana Sessa in
Google Scholar
PubMed Close
, and
for the Swiss Group for Clinical Cancer Research (SAKK)
Search for other papers by for the Swiss Group for Clinical Cancer Research (SAKK) in
Google Scholar
PubMed Close

for phase 2. Dose modifications were planned for adverse events (AEs) grade 2 (dose reduction by one dose level) and grade 3 or 4 (stop treatment with CR1447 until resolved to grade ≤2 and restart one dose level lower until end of treatment). If an

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-17-0174
Volume/Issue:
Volume 6: Issue 7
Open access
Angelica Sharma Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Angelica Sharma in
Google Scholar
PubMed Close
,
Katharine Lazarus Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Katharine Lazarus in
Google Scholar
PubMed Close
,
Deborah Papadopoulou Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Deborah Papadopoulou in
Google Scholar
PubMed Close
,
Hemanth Prabhudev Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Hemanth Prabhudev in
Google Scholar
PubMed Close
,
Tricia Tan Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Department of Clinical Biochemistry, North West London Pathology, London, UK

Search for other papers by Tricia Tan in
Google Scholar
PubMed Close
,
Karim Meeran Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Karim Meeran in
Google Scholar
PubMed Close
, and
Sirazum Choudhury Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Department of Clinical Biochemistry, North West London Pathology, London, UK

Search for other papers by Sirazum Choudhury in
Google Scholar
PubMed Close

was established with an 8-h level of 16 μg/L. Patient C ( Fig. 3C ) was weaned from a prednisolone dose of 2 to 1 mg, with an 8-h level of 19 μg/L and a 6-h level of 36 μg/L. After this dose reduction, the baseline cortisol increased to 194 mmol/L, and

Article Type:
Research Article
Collections:
Adrenal
DOI:
https://doi.org/10.1530/EC-23-0097
Volume/Issue:
Volume 12: Issue 8
Open access
Kathrin R Frey Department of Medicine I, Endocrine and Diabetes Unit, University Hospital, University of Würzburg, Würzburg, Germany

Search for other papers by Kathrin R Frey in
Google Scholar
PubMed Close
,
Tina Kienitz Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Search for other papers by Tina Kienitz in
Google Scholar
PubMed Close
,
Julia Schulz Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Search for other papers by Julia Schulz in
Google Scholar
PubMed Close
,
Manfred Ventz Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Search for other papers by Manfred Ventz in
Google Scholar
PubMed Close
,
Kathrin Zopf Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Search for other papers by Kathrin Zopf in
Google Scholar
PubMed Close
, and
Marcus Quinkler Endocrinology in Charlottenburg, Berlin, Germany

Search for other papers by Marcus Quinkler in
Google Scholar
PubMed Close

patients with CAH reported an increase in L1-L4 BMD but a decrease of femoral neck BMD after 8–10 years ( 26 ); another study including 6 PAIs and 6 secondary AIs also showed a mixed response ( 27 ). Recently, we showed that a dose reduction in daily HC

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-18-0160
Volume/Issue:
Volume 7: Issue 6
Open access
Peter Bond Department of Internal Medicine, Elisabeth TweeSteden Hospital, Tilburg, the Netherlands
Department of Performance and Image-enhancing Drugs Research, Android Health Clinic, Utrecht, the Netherlands

Search for other papers by Peter Bond in
Google Scholar
PubMed Close
,
Tijs Verdegaal Department of Internal Medicine, Elisabeth TweeSteden Hospital, Tilburg, the Netherlands
Department of Internal Medicine, Spaarne Gasthuis, Haarlem, the Netherlands

Search for other papers by Tijs Verdegaal in
Google Scholar
PubMed Close
, and
Diederik L Smit Department of Internal Medicine, Elisabeth TweeSteden Hospital, Tilburg, the Netherlands
Department of Performance and Image-enhancing Drugs Research, Android Health Clinic, Utrecht, the Netherlands

Search for other papers by Diederik L Smit in
Google Scholar
PubMed Close

or two phlebotomies to accelerate the correction of hematocrit – with the dose reduction in order to persist this – is unlikely to cause harm. This, however, might be different for periodic phlebotomy in order to maintain decreased (or ‘corrected

Article Type:
Review Article
Collections:
Reproduction
DOI:
https://doi.org/10.1530/EC-24-0283
Volume/Issue:
Volume 13: Issue 10
Open access
Daniel Bell Department of Pharmacy, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK

Search for other papers by Daniel Bell in
Google Scholar
PubMed Close
,
Julia Hale Department of Endocrinology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK

Search for other papers by Julia Hale in
Google Scholar
PubMed Close
,
Cara Go Department of Endocrinology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK

Search for other papers by Cara Go in
Google Scholar
PubMed Close
,
Ben G Challis Department of Endocrinology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK

Search for other papers by Ben G Challis in
Google Scholar
PubMed Close
,
Tilak Das Department of Radiology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK

Search for other papers by Tilak Das in
Google Scholar
PubMed Close
,
Brian Fish Department of Head and Neck Surgery, Cambridge University NHS Foundation Trust, Cambridge, UK

Search for other papers by Brian Fish in
Google Scholar
PubMed Close
, and
Ruth T Casey Department of Endocrinology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
Department of Medical Genetics, Cambridge University, Cambridge, UK

Search for other papers by Ruth T Casey in
Google Scholar
PubMed Close

identified in ten of these patients, most commonly intentional dose reductions/omissions due to nausea (four patients) or headaches (one case), along with problems obtaining a supply of medication (three patients) and unintentional non-adherence due to

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-21-0258
Volume/Issue:
Volume 10: Issue 11
Open access
Jan Calissendorff Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

Search for other papers by Jan Calissendorff in
Google Scholar
PubMed Close
and
Henrik Falhammar Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

Search for other papers by Henrik Falhammar in
Google Scholar
PubMed Close

patients (15%) had adverse effects of iodine treatment (rash n  = 2, rash and vomiting n  = 1 and swelling of fingers n  = 1). This was managed with dose reduction in two and stopping LS prematurely in two. These four women were aged 30, 35, 43 and 61

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-17-0025
Volume/Issue:
Volume 6: Issue 4
Open access
A Chinoy Royal Manchester Children’s Hospital, Manchester, UK

Search for other papers by A Chinoy in
Google Scholar
PubMed Close
,
M Skae Royal Manchester Children’s Hospital, Manchester, UK

Search for other papers by M Skae in
Google Scholar
PubMed Close
,
A Babiker King Abdullah Specialized Children’s Hospital, Riyadh, Saudi Arabia

Search for other papers by A Babiker in
Google Scholar
PubMed Close
,
D Kendall Royal Preston Hospital, Preston, UK

Search for other papers by D Kendall in
Google Scholar
PubMed Close
,
M Z Mughal Royal Manchester Children’s Hospital, Manchester, UK

Search for other papers by M Z Mughal in
Google Scholar
PubMed Close
, and
R Padidela Royal Manchester Children’s Hospital, Manchester, UK

Search for other papers by R Padidela in
Google Scholar
PubMed Close

, resolution of intercurrent illness results in normalisation of cCa, such that close monitoring and dose reduction to baseline is needed to prevent hypercalcaemia and hypercalciuria. rhPTH(1–34) may have a role in these situations. The mechanisms underlying

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-17-0234
Volume/Issue:
Volume 6: Issue 8
Open access
Marek Niedziela Department of Pediatric Endocrinology and Rheumatology, Institute of Pediatrics, Karol Jonscher’s Clinical Hospital, Poznan University of Medical Sciences, Poznan, Poland

Search for other papers by Marek Niedziela in
Google Scholar
PubMed Close

(a dose reduction or change of medication may be sufficient): 1) Pruritus, urticaria (1–5%), sometimes very severe skin symptoms – they can be controlled with antihistamines or by changing the antithyroid drug 2) Muscle and joint pain (in

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-21-0191
Volume/Issue:
Volume 10: Issue 11
Open access